Abstract
Background. Metastatic renal cell carcinoma (RCC) is rising in incidence but remains difficult to treat. This clinical trial evaluated the effects of pemetrexed (multitargeted antifolate, ALIMTA®) for the treatment of metastatic RCC. Patients and methods. Patients were required to have histological diagnosis of metastatic RCC with measurable disease and no prior chemotherapy. In addition, patients were required to have a World Health Organization (WHO) performance status of 0–2 and adequate bone marrow reserve. Patients received pemetrexed at a dose of 600 mg/m2 as a 10 min infusion every 3 weeks. Patients did not receive folic acid or vitamin B12 supplementation. Results. Thirty-nine patients were enrolled and thirty two were evaluable for response. Three patients had a partial response for a response rate of 9% (95% CI 2–25%). The median time to progressive disease was 10.5 months. Of the nonresponders, twenty two had stable disease (median duration was 5.8 months; range 1.5–27.7) and seven had progressive disease (median time to progression was 5.4 months). Median time to progression for all qualified patients was 5.7 months. Common toxicities experienced were diarrhea and infection. Fatigue, stomatitis, and rash were also reported. The most common hematologic toxicity was grade 3/4 lymphopenia in 76% of patients. Leukopenia, granulocytopenia, and thrombocytopenia were also frequently reported. Conclusion. Single-agent pemetrexed has moderate activity in the treatment of metastatic RCC and should be investigated in combination with other potential active agents, as first-line treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chapman AE, Goldstein LJ: Multiple drug resistance: biologic basis and clinical significance in renal cell carcinoma. Semin Oncol 22: 17–28, 1995
Stadler WM, Vogelzang NJ: Low dose interleukin-2 in the treatment of metastatic renal cell carcinoma. Semin Oncol 22: 67–73, 1995
Motzer RJ, Bander NH, Nanus DM: Renal-cell carcinoma. N Engl J Med 335: 865–875, 1996
Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE: Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 11: 1368–1375, 1993
Foss SD: Interferon in metastatic renal cell carcinoma. Semin Oncol 27(2): 187–193, 2000
Margolin KA: Interleukin-2 in the treatment of renal cancer. Semin Oncol 194–203, 2000
Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 338: 1272–1278, 1998
McLaughlin JK, Lipworth L. Epidemiologic aspects of renal cell cancer. Semin Oncol 27(2): 115–123, 2000
Adjei AA: Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors. Ann Oncol 11(10): 1335–1341, 2000
Calvert H: An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents. Semin Oncol 26(2 suppl 6): 3–10, 1999
Moran RG: Roles of folylpoly-γ-glutamate synthetase in therapeutics with tetrahydrofolate antimetabolites: an overview. Semin Oncol 26(2 suppl 6): 24–32, 1999
Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M, Schultz RM: LY231514, a pyrrolo [2,3–d] pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57(6): 1116–1123, 1997
Schultz RM, Chen VJ, Bewley JR, Roberts EF, Shih C, Dempsey JA: Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin Oncol 26(2 suppl 6): 68–73, 1999
Rinaldi DA, Kuhn JG, Burris HA, Dorr FA, Rodriguez G, Eckhardt SG, Jones S, Woodworth JR, Baker S, Langley C, Mascorro D, Abrahams T, Von Hoff DD: A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 44(5): 372–380, 1999
Green S, Weiss GR: Southwest Oncology Group standard response criteria, endpoint definitions, and toxicity criteria. Invest New Drugs 10(4): 239–253, 1992
Niyikiza C, Baker SD, Seitz DE, Walling JM, Nelson K, Rusthoven JJ, Stabler SP, Paoletti P, Calvert AH, Allen RH: Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 1: 545–552, 2002
Bunn P, Paoletti P, Niyikiza C, Rusthoven J, Nelson K, Hanauske A, Stabler S, Calvert H, Allen R: Vitamin B12 and folate reduce toxicity of ALIMTA (pemetrexed disodium, LY231514, MTA), a novel antifolate/antimetabolite. Proc Am Soc Clin Oncol 76a: A300, 2001
Hammond L, Villalona-Calero M, Eckhardt SG, Drengler R, Aylesworth C, Johnson T, Hidalgo M, Rodriguez G, Diab S, Monroe P, Thornton D, Von Hoff D, Rowinsky E: A phase I and pharmacokinetic (PK) study of the multitargeted antifol (MTA) LY231514 with folic acid. Proc Am Soc Clin Oncol 17: 225a, 1998 (Abstract 866)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Thödtmann, R., Sauter, T., Weinknecht, S. et al. A phase II trial of pemetrexed in patients with metastatic renal cancer. Invest New Drugs 21, 353–358 (2003). https://doi.org/10.1023/A:1025480914273
Issue Date:
DOI: https://doi.org/10.1023/A:1025480914273